anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. 

ORFADIN was studied in one open-label, uncontrolled study of 207 patients with HT-1, ages 0 to 22 years at enrollment (median age 9 months), who were diagnosed with HT-1 by the presence of succinylacetone in the urine or plasma. The starting dose of ORFADIN was 0.3 to 0.5 mg/kg twice daily, and the dose was increased in some patients to 1 mg/kg twice daily based on weight, biochemical, and enzyme markers. The recommended starting dosage of ORFADIN is 0.5 mg/kg twice daily [see Dosage and Administration (2.1)]. Median duration of treatment was 22 months (range 0.1 to 80 months). 

The most serious adverse reactions reported during ORFADIN treatment were thrombocytopenia, leukopenia, porphyria, and ocular/visual complaints associated with elevated tyrosine levels [see Warnings and Precautions (5.1, 5.2)]. Fourteen patients experienced ocular/visual events. The duration of the symptoms varied from 5 days to 2 years. Six patients had thrombocytopenia, three of which had platelet counts 30,000/microL or lower. In 4 patients with thrombocytopenia, platelet counts gradually returned to normal (duration up to 47 days) without change in ORFADIN dose. No patients developed infections or bleeding as a result of the episodes of leukopenia and thrombocytopenia. 

Patients with HT- 1 are at increased risk of developing porphyric crises, hepatic neoplasms, and liver failure requiring liver transplantation. These complications of HT-1 were observed in patients treated with nitisinone for a median of 22 months during the clinical trial (liver transplantation 13%, liver failure 7%, malignant hepatic neoplasms 5%, benign hepatic neoplasms 3%, porphyria 1%). 

The most common adverse reactions reported in the clinical trial are summarized in Table 1. 

Adverse reactions reported in less than 1% of the patients, included death, seizure, brain tumor, encephalopathy, hyperkinesia, cyanosis, abdominal pain, diarrhea, enanthema, gastrointestinal hemorrhage, melena, elevated hepatic enzymes, liver enlargement, hypoglycemia, septicemia, and bronchitis.
The invention discloses an anti-thrombus aggregation and anti-coagulation compound preparation able to reduce gastric acid stimulation. The compound preparation is characterized by being prepared from 2-180 parts of aspirin, 10-50 parts of heavy magnesium carbonate, and 5-30 parts of Dihydroxyaluminium Aminoacetate, wherein the aspirin and the alkaline drug heavy magnesium carbonate, Dihydroxyaluminium Aminoacetate are at different inner and outer layers. At the same time, an inclusion material is used in the aspirin layer and a buffer layer to prepare an inclusion compound, thus solving the problem of isolating the aspirin layer (acidic drug) from the alkaline drugs to prevent reaction during preparation, and also solving the reaction problem of the acidic drug and the alkaline drugs after the compound preparation enters the stomach by oral taking. The alkaline drugs can neutralize gastric acid so as to improve gastric acid increase, direct stimulation on gastric mucosas, epigastric pain and other clinical symptoms. The alkaline drugs also can accelerate gastric emptying, and make aspirin quickly enter the small intestine to speed up absorption. The invention simultaneously discloses application of the compound preparation in preparation of anti-platelet aggregation or anti-coagulation drugs, especially in preparation of drugs treating unstable angina pectoris, acute myocardial infarction, ischemic cerebrovascular disorder and other aspects.
The invention relates to a preparation method for enalapril maleate orally disintegrating tablets. The formula comprises the following ingredients, by weight, enalapril maleate, diluents, disintegrating agents, lubricants and corrective agents with a ratio of 1:(5-6):(3.5-4.5):(0.1-0.3):(0.05-0.15). The diluents, the disintegrating agents, the lubricants and the corrective agents can be substances generally used in pharmaceutical field. Enalapril maleate is crushed by a micropowder machine, and the particle sizes of 90% of the particles are less than 80 microns. Then the diluents, part of the disintegrating agents, the corrective agents are added, mixed uniformly and subjected to dry granulation. Then part of the disintegrating agents, the lubricants are added, mixed totally, and subjected to tabletting, and enalapril maleate orally disintegrating tablets are obtained. The enalapril maleate orally disintegrating tablets are advantaged by rapid disintegration, rapid onset, high absorption and high bioavailability. The enalapril maleate orally disintegrating tablets can reduce irritation effects of medicines on oesophaguses and gastrointestinal tracts and are well suitable for some critical patients to take.
Eligible patients after signing informed consent will undergo study evaluation and acetylation status typing before being treated. Patients will begin treatment (day -7) with a daily dose of a slow-release formulation of hydralazine tablets containing either 182 mg for rapid-acetylators or 83 mg for slow-acetylators and slow-release tablets containing 700mg of magnesium valproate at a dose of 40mg/Kb t.i.d. Both hydralazine and magnesium valproate will be administered from day -7 until the last day of the last chemotherapy cycle. Chemotherapy will initiate at day 1 (after seven days of being taken hydralazine and magnesium valproate) with the same pre-study protocol regimen at which patients showed tumor progression. Toxicity will be evaluated after each course of chemotherapy. Response will be evaluated at the third course of chemotherapy. Promoter of selected genes will be evaluated by methylation-specific PCR in serum DNA before and after 7 days of treatment with hydralazine and valproate.
Method and device for regeneration of cells in pathogenic organs of living organisms, with implementation in the human and veterinary medicine, in diagnostics and therapy for restoring the energy state of the living organisms, as well as their tissues, organs and systems. By this method a direct effect is achieved on the pathological organs and systems of the living organism, as well as the causes for the disbalance are influenced in the own information field - the homeostasis of the organism, by removing the accumulated intoxications in the cells, tissues, organs and systems of the whole organism. The device allows a smooth regulation of the intensity of the light energy, directed onto the biological subject during therapy. With this method information is obtained for the variations from the normal values of the bioconstants of the human organism, the influence of the external pathogenic factors on the organism is studied, to which remedial vibrations of medicaments, herbs, foodstuffs, etc. are given for consumption. Simultaneously with the exploration a neutralization is carried out of the external pathogenic factors, a remedial schedule is drafted, a multiple current complete diagnostics of the organism is made, and the results are represented in graphs and tables. The homeostasis of the body tissues, internal organs and systems of the organism is restored by processing of all organs with light energy in the frequency spectrum of the invisible green light , and the human organism is given also a vibration from optically activated distilled water, which is consumed until full balance is achieved between the internal organs of the organism and the normal values of the bioconstants in it.
Immunomagnetic enrichment of cell populations from bodily fluids followed by immunofluorescent labeling is an established sample preparation method often used for the detection and enumeration of rare cells such as circulating tumor cells. For a detailed analysis of the heterogeneous characteristics of these cells, the cells need to be retrieved individually. Although several technologies are available to obtain 100% pure cells either individually or in bulk, these are often expensive, have low specificity, or suffer from high cell losses, either inherent to the technology or caused by sample transfer into special chips. To solve this issue, we introduce the magnetic micro-needle approach, which allows for the isolation of immunomagnetically labeled target cells by the use of a magnetized microneedle directly from glass slides. The magnetic microneedle approach makes use of the already present magnetic labeling used for enrichment, while the glass-slide-based open sample container allows for easy and loss-free sample loading. Additionally, the system facilitates not only the isolation but also the precise placement of cells. As the used parts are low cost, the technology provides researchers with an affordable and efficient method to pick up and isolate, as well as specifically place magnetically labeled cells from enriched fractions, thereby enabling the researchers to isolate or analyze these rare cells in more detail.
This group will have undergone cataract surgery at least 2 months before conducting a questionnaire. Patients enrolled in this group had cataract surgery with a 2.5 add ReSTOR lens in one eye and a 3.0 add lens in the other.
OBJECTIVE: Venous aneurysms are rare vascular abnormalities associated with venous thromboembolism. In this study, we presented our experience in managing thrombosed lower extremity venous aneurysms and evaluate the impact of vitamin D deficiency and genetic thrombophilic risk factors on patient management and outcomes.
METHODS: A single-center retrospective observational analysis was conducted on ten patients with thrombosed lower limb venous aneurysms who underwent surgical procedures at our hospital from July 2014 to February 2023. Collected data included venous duplex ultrasonographic imaging and laboratory tests including genetic thrombophilic risk factors and assessments of vitamin D levels.
RESULTS: There were 5 males and 5 females. The mean age was 46.6 ± 12.1 years. The aneurysms were located in the popliteal vein in three patients, the great saphenous vein in six, and the small saphenous vein in one. Venous duplex imaging revealed saccular aneurysms in eight patients and fusiform aneurysms in two, with a mean diameter of 37.2 ± 10.6 mm, ranging from 23 to 52 mm. Laboratory tests indicated vitamin D deficiency in all of the patients, and genetic thrombophilic risk factors were identified in two cases. Surgical interventions consisted of tangential excision with lateral venorrhaphy in three patients and total excision and ligation in seven patients. The postoperative period was favorable for all patients.
CONCLUSIONS: Surgical treatment of thrombosed venous aneurysms in the lower extremities is essential to prevent complications such as thromboembolism. A comprehensive approach, including knowledge of genetic risk factors and vitamin D levels, may improve patient outcomes.
Right handed healthy individuals aged 18-40 will be eligible to participate. Participants will be randomized in a 1:1:1 ratio to receive real or placebo 2mA tDCS delivered for 20 minutes while performing a 3 hour computerized cued Stroop task. Groups will receive real or sham stimulation during the first 20 minutes or 90-110 minutes into the task. Groups will be: 1) Sham (sham given at both time points); 2) Prevent (real will be given during first 20 minutes to try to prevent or delay fatigue and sham given at second time point); or 3) Rescue (sham will be given initially and real given at 90-110 minutes to see if performance can be rescued after fatigue has set in). The primary outcome measure will be the slope of change for intra-individual variability of response time for correct items and regression models will be used to determine whether real preventative or rescue tDCS alters the rate of performance change relative to sham stimulation. Accuracy and mean response time will also be examined as secondary outcomes.
It is an object of the present invention to provide a highly reliable image database system capable of accessing image data at high speed regardless of the increase of the image data and capable of controlling the image data as a whole. A storage unit 1, a control unit 2, an image database server 3 and a DICOM gateway 4 are subjected with each other to network connection. The storage unit 1 stores medical image data. The control unit 2 controls the storage unit. The image database server 3 stores key information associated with the image data stored and applies relay processing between an externally connected viewer and the image database server. The DICOM gateway 4 applies relay processing via a DICOM protocol between a plurality of modality devices externally connected with the image database server and the DICOM gateway. A control unit group, an image database server group, and a DICOM gateway group are constituted by providing at least a plurality of control units, a plurality of image database servers and a plurality of DICOM gateways, and a load balancer for executing load distribution control of every group is provided for every group based on header information of a request.
Objective To explore the efficacy and the optimal dose of sufentanil in PCIA in patients underwent moderate surgery for the purpose of providing reference in clinical practice.

Methods 60 patients aging from 20 to 75，BMI 18 to 28 kg/m2，American Society of Anesthesiologists (ASA) grade I to II, anticipated surgery duration within 4 hrs and agreed to sign consent paper were scheduled for selective moderate surgery(including abdominal surgery and arthroplasty). Exclusive criteria: severe respiratory, cardiovascular or neurological disease, hepatic or renal dysfunction, psychiatric history or with unstable mental state, drug addiction or dependence. All patients were randomly assigned into 3 groups, S1 received 1.5 ug/kg sufentanil in PCIA, S2 received 2.0 ug/kg sufentanil, S3 received 2.5 ug/kg sufentanil. All patients received general anesthesia which was induced with midazolam 2mg, sufentanil 0.5ug/kg, propofol 2mg/kg, cisatracurium 0.2mg/kg and was maintained with continuous infusion of propofol, remifentanil and cisatracurium to maintain bispectral index (BIS) value between 40 and 60. Monitoring of MAP, heart rate (HR), pulse oxymetry (SpO2%), End-tidal CO2 (ETCO2), blood loss, and transfusion were recorded during anesthesia.

After patient waked, a loading dose of 10 ug sufentanil was given per time according to the patients' pain level and the loading dose was repeated till the pain relived or the RR was less than 10 times per min. Then the patient-controlled analgesia (PCA) pump was attached, and the continuous infusion speed was set at 2 ml/h. The pump was set to give an amount of 0.5ml at each press with a lockout interval of 10min. Patient was observed in the PACU for at least 30 min until the discharge criteria was reached. All the patients were followed-up at 2h, 6h, 24h and 48 h after the surgery. Clinical evaluations included MAP, HR, respiratory rate (RR), SpO2%, total pressing times, total amount of sufentanil, additional analgesic requirement, VAS, numerical rating scale (NRS) and Ramsey sedation scale were recorded. Side effects include nausea and vomiting, urinary retention, pruritus, respiratory depression were also recorded. Overall satisfaction index were inquired as well.
Background/Objectives: Personalized and self-initiated dietary adjustments have been shown to alleviate mental and somatic complaints. Here, we investigated the potential role of gut microbiome alterations underlying these effects. Methods: For this purpose, participants (n = 185) underwent a four-week self-initiated dietary intervention and filled out weekly questionnaires on their dietary intake, somatic and mental symptoms, and physical activity. Results: Overall, the participants lost weight, had alleviated mental and somatic complaints, reduced their total caloric and percentual carbohydrate intake, and ate less processed, party-type, and traditional Dutch food items, but ate more Pescatarian type food items, while keeping their fiber intake unaltered. Baseline and endpoint gut microbiota analyses using 16S rRNA gene sequencing revealed an overall increase in Gemmiger formicilis and reductions in Peptostreptococcaceae and Ruminococcus bromii over the four-week dietary intervention. While these bacterial alterations were considered to be beneficial for the host, they were not individually correlated with alterations in, or endpoint levels of, somatic and/or mental complaints. Instead, individual increases in Ruminococcus bicirculans (a well-known utilizer of plant cell wall polysaccharides) were strongly correlated with reductions in mental complaints, even though overall R. bicirculans remained unaltered over the course of the four-week self-initiated dierary intervention. Conclusions: Our results suggest that overall altered versus individually correlated microbiota abundances and their relations with host health characteristics over the course of a self-chosen dietary intervention may represent different levels of regulation, which remain to be further untangled.
Semaglutide is the second marketed glucagon-like peptide 1 receptor agonist that can be used safely and efficiently in non-diabetic people with excess weight, providing a new milestone in the pharmacological treatment of obesity. This narrative review aims to describe the clinical actions of this new drug in weight management in non-diabetic patients along with possible side-effects and dropout reasons. To accomplish this, the PubMed database was searched to retrieve the most relevant clinical studies published to date on this topic, using the following keywords "semaglutide and obesity". Currently, semaglutide is on the market in two formulations, the once-weekly subcutaneous (s.c.) semaglutide and once-daily oral semaglutide. Data in the literature on the anti-obesity action of semaglutide are available for both routes of administration of the drug, with a prevalence of studies using the s.c. one. However, given its dosage, oral semaglutide may provide greater attractiveness and better treatment adherence, but further research is needed in this field.
Each MHC group participant (n=30) was brought to the procedure room by its mother. The mother sat in a comfortable chair with back support. She held her baby close to her chest, with the baby's head in a crossed position so that it could see its mother. The same nurse collected the blood sample. The mother communicated with the baby verbally and made eye contact with it to calm it down during the procedure. She was holding the baby both during and after the procedure.
The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
This is an open-label Phase 1/2a clinical study. The study will be conducted in two parts: Part I: Phase 1 dose escalation, TJ011133 is tentatively scheduled to be administered once weekly in 28-day treatment cycles;Part II: Phase 2a study TJ011133 will be administered at a dose of 30 mg/kg once weekly, and AZA will be administered at a dose of 75 mg/m2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.
Patients undergoing allogeneic SCT will receive standard GVHD prophylaxis consisting of a calcineurin inhibitor and methotrexate or mycophenolate mofetil. Patients developing grade I/II acute GVHD will be treated by IV or oral methylprednisolone 1-2 mg/kg/day and oral cannabidiol at a starting dose of 10 mg twice daily. Doses of cannabidiol can be escalated every day according to clinical response to a maximal dose of 600 mg/day,if no significant drug related side effects present (CTCAE3 grade\>2). Cannabidiol will be given up to 90 days.
PURPOSE:To obtain powder, containing powdery metallic soap, cosmetic powder and preferably further oily ingredient and capable of preventing makeup disorder by applying onto the cosmetics, e.g. foundation, makeup powder, etc. CONSTITUTION:The titled powder containing 25-50wt% powdery metallic soap, e.g. Ca alkyl phosphate, 42-75wt% cosmetic powder, e.g. talc, mica, kaolin or titanium oxide, and preferably further <=8wt% oily ingredient, e.g. silicone oil or liquid paraffin. The powder is capable of completely preventing makeup disorder of an O/W type emulsion system or water dispersion system cosmetic caused by sweat. Since high adhesive property and water repellency are imparted, cosmetics are resistant to water from the outside, e.g. swimming, etc. Furthermore, since the usage is simple and the powder can be reapplied when placed in an environment likely to upset makeup.
The specific aims of the current research protocol are as follows: Aim 1: To test the hypothesis that SIP training of individuals with ABI will improve processing speed. This study is expected to demonstrate that individuals with ABI that receive SIP training will improve on neurocognitive measures of processing speed. Aim 2: To test the generalizability of SIP training of individuals with TBI to other cognitive domains beyond information processing speed. This study is expected to demonstrate increases in working memory, attention and executive functioning in the group that receives the cognitive training. Aim 3: To test the hypothesis that SIP training of individuals with TBI will improve mood. This study is expected to demonstrate that self-reported levels of depression will improve in the group that receives cognitive training. Aim 4: To examine if changes in the neural integrity of white matter pathways of the brain occur in individuals that undergo the SIP training.

All participants will undergo a set of baseline cognitive exams/tests, which will take approximately two hours. Participants will be randomly placed in either the experimental group or the control group. The experimental group will undergo approximately 40 hours of training on the Brain Fitness Program over an eight week period. The control group will be contacted once a week for eight weeks about their cognitively stimulating activities (i.e. reading, working on the computer, and puzzles). At approximately the thirteenth week participants from both groups will undergo post-baseline cognitive exams/tests. This evaluation will take approximately two hours. In addition there is an optional neuroimaging study which participants may elect to participate in. Participants who agree to take part in the neuroimaging portion of the study will undergo a baseline MRI scan. At approximately 13 weeks later participants will undergo a post-baseline MRI scan. Both scans will take approximately one hour.